Last updated: 2026-10-13 21:00:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Alumis Inc. (ALMS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.58, with a market capitalization of $926.76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.37 to $31.35. This page covers its latest market performance, valuation, price trends and company information.
$926.76M | |
$7.01 | |
$31.35 | |
$2.76 | |
$7.06 | |
1.58M | |
2.47M | |
-- | |
$31.35 | |
$4.37 | |
-- | |
-- |
Alumis Inc. (ALMS) is trading at $6.58 in after-hours trading as of 2026-10-13 20:51:00, down 6.87% ($0.48) from the regular-session close of $7.06.
After-hours trading shows how investors are pricing ALMS after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Alumis Inc. (ALMS) moved from $6.85 to $6.58, representing a decline of 3.90% ($0.27).
The stock traded between $6.55 and $7.31 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 2.32 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.2%
ALMS is currently trading at $6.58, placing it 8.2% of the way from its 52-week low of $4.37 to its 52-week high of $31.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 239 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alumis Inc. (ALMS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.